Copyright
©The Author(s) 2024.
World J Diabetes. Apr 15, 2024; 15(4): 591-597
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.591
Published online Apr 15, 2024. doi: 10.4239/wjd.v15.i4.591
CKD stages | 1-2 | 3a | 3b | 4 | 5 | Ref. |
HbA1c | 0.576 (64) | 0.266 (56) | 0.266 (56) | 0.296 (36) | 0.296 (36) | Lu et al[17] |
0.68 (33) | 0.52 (43) | 0.22 (14) | Ling et al[18] | |||
0.79 (14) | 0.79 (14) | 0.34 (29) | 0.34 (29) | Lo et al[19] | ||
0.38 (25) | 0.38 (25) | Vos et al[20] | ||||
0.78 (80) | 0.78 (80) | 0.78 (80) | 0.78 (80) | Zelnick et al[12] | ||
Glycated albumin | 0.54 (25) | 0.54 (25) | Vos et al[20] | |||
Fructosamine | 0.78 (80) | 0.78 (80) | 0.78 (80) | 0.78 (80) | Zelnick et al[12] | |
0.71 (80) | 0.71 (80) | 0.71 (80) | 0.71 (80) | Zelnick et al[12] |
- Citation: Zhang XM, Shen QQ. Application and management of continuous glucose monitoring in diabetic kidney disease. World J Diabetes 2024; 15(4): 591-597
- URL: https://www.wjgnet.com/1948-9358/full/v15/i4/591.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i4.591